PE20141115A1 - Comprimido de desintegracion oral - Google Patents
Comprimido de desintegracion oralInfo
- Publication number
- PE20141115A1 PE20141115A1 PE2013001471A PE2013001471A PE20141115A1 PE 20141115 A1 PE20141115 A1 PE 20141115A1 PE 2013001471 A PE2013001471 A PE 2013001471A PE 2013001471 A PE2013001471 A PE 2013001471A PE 20141115 A1 PE20141115 A1 PE 20141115A1
- Authority
- PE
- Peru
- Prior art keywords
- active ingredient
- fine granules
- pharmaceutically active
- copolymer
- methyl methacrylate
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 abstract 4
- 239000008187 granular material Substances 0.000 abstract 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 1
- -1 HYDROXYPROPYLMETHYL Chemical class 0.000 abstract 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical group CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 abstract 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427384P | 2010-12-27 | 2010-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141115A1 true PE20141115A1 (es) | 2014-09-12 |
Family
ID=45509604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001471A PE20141115A1 (es) | 2010-12-27 | 2011-12-26 | Comprimido de desintegracion oral |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130273157A1 (enExample) |
| EP (1) | EP2658530A2 (enExample) |
| JP (1) | JP2014501224A (enExample) |
| KR (1) | KR20140007364A (enExample) |
| CN (1) | CN103402500A (enExample) |
| AR (1) | AR084610A1 (enExample) |
| AU (1) | AU2011350396A1 (enExample) |
| BR (1) | BR112013014875A2 (enExample) |
| CA (1) | CA2823166C (enExample) |
| CL (1) | CL2013001793A1 (enExample) |
| CO (1) | CO6731132A2 (enExample) |
| CR (1) | CR20130327A (enExample) |
| EA (1) | EA028217B1 (enExample) |
| EC (1) | ECSP13012718A (enExample) |
| MA (1) | MA34768B1 (enExample) |
| MX (1) | MX2013007588A (enExample) |
| PE (1) | PE20141115A1 (enExample) |
| PH (1) | PH12013501391A1 (enExample) |
| SG (2) | SG10201602311XA (enExample) |
| TN (1) | TN2013000220A1 (enExample) |
| TW (1) | TW201304823A (enExample) |
| UY (1) | UY33841A (enExample) |
| WO (1) | WO2012091153A2 (enExample) |
| ZA (1) | ZA201304617B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2254556A2 (en) | 2008-03-11 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TW202332423A (zh) * | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| WO2018209257A1 (en) * | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
| MY200542A (en) * | 2017-07-10 | 2024-01-02 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
| CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
| JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
| JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
| JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法 |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| PT1121103E (pt) | 1998-05-18 | 2007-02-28 | Takeda Pharmaceutical | Comprimidos de desintegração oral compreendendo um benzimidazole |
| ES2237121T3 (es) | 1998-07-28 | 2005-07-16 | Takeda Pharmaceutical Company Limited | Preparacion solida disgregable rapidamente. |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| WO2001083473A1 (en) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
| CA2409044C (en) | 2000-05-15 | 2013-02-19 | Takeda Chemical Industries, Ltd. | Improved recrystallization processes for obtaining anhydrous optically active lansoprazole |
| KR20100002278A (ko) | 2000-12-01 | 2010-01-06 | 다케다 야쿠힌 고교 가부시키가이샤 | (ｒ)- 또는 (ｓ)-란소프라졸의 결정 |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20050214371A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| US9486446B2 (en) * | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| EP2254556A2 (en) * | 2008-03-11 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
| WO2010008569A1 (en) * | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
-
2011
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Withdrawn
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 PH PH1/2013/501391A patent/PH12013501391A1/en unknown
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en not_active Ceased
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2823166A1 (en) | 2012-07-05 |
| ZA201304617B (en) | 2014-08-27 |
| AU2011350396A1 (en) | 2013-07-11 |
| US20130273157A1 (en) | 2013-10-17 |
| WO2012091153A2 (en) | 2012-07-05 |
| ECSP13012718A (es) | 2013-12-31 |
| CA2823166C (en) | 2019-04-09 |
| EA028217B1 (ru) | 2017-10-31 |
| BR112013014875A2 (pt) | 2016-10-18 |
| AR084610A1 (es) | 2013-05-29 |
| CO6731132A2 (es) | 2013-08-15 |
| MX2013007588A (es) | 2013-08-09 |
| CN103402500A (zh) | 2013-11-20 |
| WO2012091153A3 (en) | 2012-09-07 |
| SG190905A1 (en) | 2013-07-31 |
| JP2014501224A (ja) | 2014-01-20 |
| CL2013001793A1 (es) | 2013-12-06 |
| KR20140007364A (ko) | 2014-01-17 |
| TW201304823A (zh) | 2013-02-01 |
| CR20130327A (es) | 2013-08-22 |
| SG10201602311XA (en) | 2016-04-28 |
| PH12013501391A1 (en) | 2013-08-28 |
| TN2013000220A1 (en) | 2014-11-10 |
| MA34768B1 (fr) | 2013-12-03 |
| EA201390981A1 (ru) | 2014-07-30 |
| UY33841A (es) | 2012-07-31 |
| EP2658530A2 (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012718A (es) | Comprimido de desintegración oral | |
| UY33201A (es) | Compuestos de pirazol como antagonistas de crth2. | |
| EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| AR094548A1 (es) | Dispersión sólida físicamente estable | |
| MX375936B (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| MX2017006858A (es) | Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol. | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| MX2017003561A (es) | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. | |
| CO6382109A2 (es) | Formulación de depósito de octreotida con niveles de exposición constantemente altos | |
| CL2017001186A1 (es) | Comprimido multicapa que contiene un fármaco inestable a la luz | |
| CY1119542T1 (el) | Προϊον μικρονισμου που περιλαμβανει οξεικη ουλιπρισταλη | |
| CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| MX2015010449A (es) | Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos. | |
| ECSP13012832A (es) | Compuestos de pirazol como antagonistas de crth2 | |
| JOP20170127A1 (ar) | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات | |
| AR071706A1 (es) | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. | |
| BR112015023381A2 (pt) | composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido | |
| PE20131064A1 (es) | Preparacion de particulas recubiertas | |
| AR081929A1 (es) | Formulaciones de levetiracetam de liberacion controlada y metodos para su produccion | |
| MX361275B (es) | Formulacion de capsula de acido 5-aminosalicilico. | |
| EA201170880A1 (ru) | Таблетка с контролируемым высвобождением с малой дозой активного вещества | |
| JP2013082696A5 (enExample) | ||
| AR083322A1 (es) | Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |